← Back to Home

A new option for kidney cancer after immunotherapy: belzutifan combination recommended by EU experts

A phase 3 trial showed that belzutifan plus lenvatinib can delay progression of advanced clear cell kidney cancer, but the overall survival benefit did not reach statistical significance. EU marketing authorization still awaits a European Commission decision, with anemia and hypoxia key considerations alongside efficacy.

By SURL BioNews

When immunotherapy can no longer control advanced kidney cancer, whether the next treatment can keep the disease stable for longer is a difficult question for patients and their care teams. Belzutifan plus lenvatinib has now moved a step closer to an additional EU indication: an expert committee has recommended the oral combination, primarily on evidence that it delays disease progression. The trial did not provide a statistically clear answer on whether it prolongs life.

On November 12, 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the combination for adults with advanced clear cell renal cell carcinoma whose disease progressed after treatment that included a PD-1 or PD-L1 inhibitor. This marks progress in the review of an additional indication; European Commission approval is still required. MSD said a decision is expected within two months, while EMA said updated product information would be published after the Commission’s decision.

The two drugs act at different points. Belzutifan inhibits hypoxia-inducible factor HIF-2α, disrupting gene signaling associated with tumor growth and angiogenesis; lenvatinib inhibits multiple tyrosine kinases, including vascular endothelial growth factor receptors. The combination brings different mechanisms of action to treatment options after immunotherapy, but its value must still be assessed through clinical comparison.

The phase 3 LITESPARK-011 trial supporting the recommendation randomly assigned 747 patients to the combination or cabozantinib. The study was open-label, meaning patients and physicians knew the treatment assignments, but imaging-based efficacy assessments were conducted by an independent central team blinded to those assignments. The analysis used to support this recommendation showed a 26% relative reduction in the risk of disease progression or death with the combination, with a hazard ratio of 0.74. This measure assesses progression-free survival and cannot be interpreted directly as a 26% reduction in the risk of death.

Tumor shrinkage results also favored the combination. In the final analysis, the objective response rate was 53.1%, compared with 40.2% in the cabozantinib group; among patients who responded to treatment, median duration of response was 22.0 months and 11.9 months, respectively. However, the other co-primary endpoint—overall survival—did not reach statistical significance: the hazard ratio for death was 0.85, with a 95% confidence interval of 0.70 to 1.03, which still included the possibility of no difference between the groups.

Efficacy was accompanied by a substantial treatment burden. According to the final safety analysis cited by *Urology Times*, grade 3 or higher adverse events occurred in 85.4% of the combination group and 83.0% of the cabozantinib group; anemia and hypoxia were more common with the combination. Similar overall adverse event rates do not mean the two regimens carry the same risks, nor do these events alone establish that all were caused by the drugs.

This positive opinion brings another potentially approvable treatment option for advanced kidney cancer after immunotherapy. Current evidence supports its ability to delay progression and improve tumor response, but has yet to establish an overall survival benefit. If the European Commission approves the combination, both sides of this evidence, along with the differing side effect burdens, will inform assessments of its place in treatment.

References

  1. Merck
  2. European Medicines Agency
  3. OncLive
  4. Urology Times